|Bid||21.01 x 900|
|Ask||21.70 x 800|
|Day's Range||21.42 - 21.94|
|52 Week Range||8.85 - 24.33|
|Beta (5Y Monthly)||1.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 22, 2023 - Feb 27, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.17|
PARSIPPANY, N.J., November 17, 2022--Iveric Bio announced that the U.S. FDA has granted Breakthrough Therapy designation for avacincaptad pegol (ACP, also known as Zimura).
PARSIPPANY, N.J., November 04, 2022--Iveric Bio announced that members of the management team will participate in fireside chats at the three investor conferences in November.
Representing IVERIC Bio today are Glenn Sblendorio, chief executive officer; Dr. Pravin Dugel, president; Keith Westby, chief operating officer; David Carroll, chief financial officer; Dr. Dhaval Desai, chief development officer; Chris Simms, chief commercial officer; and Tony Gibney, chief business and strategy officer. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date.